Pharmaceutical solution for oral dosage
AssigneeLiqmeds Worldwide Limited
InventorsSandip MEHTA, Manish Kumar UMRETHIA, Jayanta MANDAL
Life of this patent
Estimating the term…
Abstract
This disclosure relates to pharmaceutical compositions in the form of a solution for oral delivery. Particularly, the pharmaceutical compositions comprise an active pharmaceutical ingredient, a buffering agent, and water. In some embodiments, the pH of the composition is from about pH 5 to about pH 8. In some embodiments, the active pharmaceutical ingredient is selected from ramipril, solifenacin, vigabatrin, losartan potassium, warfarin, and melatonin.
Claims20
1-9. (canceled)
A liquid pharmaceutical composition consisting of:
- a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, wherein the vigabatrin is present in the composition in the range of about 1 mg/mL to about 250 mg/mL;
- a preservative;
- a buffering agent;
- a sweetener;
- at least one of a flavoring agent, a solubilizer, a co-solvent, an antioxidant, a surfactant, an antifoaming agent, a chelating agent, a suspending agent, a viscosity builder, and a coloring agent;
- and
- quantum sufficit (q.s.) water;
- wherein the liquid pharmaceutical composition is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%;
- wherein the total impurities are defined as the sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months.
A liquid pharmaceutical composition comprising:
- a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, at about 1 mg/mL to about 250 mg/mL;
- a preservative in a range of about 0.001 wt % to about 1 wt %;
- a sweetener in a range of about 0.05 wt % to about 40 wt %;
- and
- quantum sufficit (q.s.) water;
- wherein the liquid pharmaceutical composition has a pH from about pH 5 to about pH 8 and is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%, and
- wherein the total impurities are defined as a sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months,
- with the proviso that the liquid pharmaceutical composition does not comprise any active pharmaceutical ingredient other than vigabatrin.
A liquid pharmaceutical composition comprising:
- a therapeutically effective amount of vigabatrin, or a pharmaceutically acceptable salt thereof, at about 1 mg/mL to about 250 mg/mL;
- a preservative in a range of about 0.001 wt % to about 1 wt %;
- one or more excipients in a range of about 0.001 wt % to about 50 wt % and selected from:
- a sweetening agent, a flavoring agent, a buffering agent, a solubilizer, a co-solvent, an antioxidant, a surfactant, an antifoaming agent, a chelating agent, a suspending agent, a viscosity builder, and a coloring agent;
- and
- quantum sufficit (q.s.) water;
- wherein the liquid pharmaceutical composition has a pH from about pH 5 to about pH 8 and is stable up to 3 months at room temperature with total impurities up to 3 months being less than 0.06%, and
- wherein the total impurities are defined as a sum of any components that are not initially present in the composition at time 0 but that are present in the composition at up to 3 months,
- with the proviso that the liquid pharmaceutical composition does not comprise any active pharmaceutical ingredient other than vigabatrin.
Dependencies are inferred from the claim text.